Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

Condition hub

Perimenopause and GLP-1

Around 78 percent of UK private GLP-1 patients in 2026 are women, with the peak age band sitting at 30 to 49, meaning a meaningful share is in perimenopause. Perimenopausal weight gain is metabolically distinct: oestrogen decline drives visceral fat redistribution, insulin sensitivity drops, and resting metabolic rate falls. GLP-1 medications (semaglutide, tirzepatide) act on the insulin-resistance side, and HRT can co-prescribe alongside them. PeptideClear publishes editorial commentary on the interaction; clinical decisions are for the reader and a UK-licensed prescriber.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

Why perimenopause weight is different

HRT and GLP-1: what is known

Pages that thread together for perimenopausal women

  • · NHS access overview for the route options if private GLP-1 is not suitable.
  • · GLP-1 and protein, lean-mass preservation is the highest-leverage habit in this age band.
  • · Aftercare, regain risk does not change with age, but bone density makes regain-cycling worse.
  • · Clinics, pick a clinic that coordinates with your HRT prescriber, not one that ignores it.
Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-19